Skip to content
DataLookout
Menu

NCT05468242

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Enrollment target: 60 to 116v3 Show 7 more changesShow less
    • Primary and study completion dates: Feb 1, 2024 to Dec 30, 2024
    • Primary endpoints: 2 to 1
    • Eligibility criteria shortened, about 3 words
    • Start date: Feb 1, 2022 to Jan 1, 2022
    • Interventions: Antivascular therapy concurrent with radiotherapy (Drug), Bevacizumab (Drug), Chemotherapy concurrent with radiotherapy (Drug), Neoadjuvant… to Bevacizumab (Drug), Neoadjuvant chemo-immunotherapy (Drug), Radiotherapy (Radiation), Tislelizumab (Drug)
    • Secondary endpoints: 3 to 4
    • Study title shortened, about 4 words
  3. Minor Secondary endpoints: details revised at 3 of 3 entriesv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression free survival
Timeframe: 2-year

Secondary (4)

Overall survival
Adverse Event
Health-related Quality of Life
Objective response rate

Arms and interventions

Neoadjuvant Chemotherapy Plus Tislelizumab + BevacizumabExperimental

Patients in experimental group will receive Tislelizumab consolidation (200 mg/q3w) after the neoadjuvant chemotherapy plus Tislelizumab + Bevacizumab and concurrent chemoradiotherapy.

Neoadjuvant Chemotherapy Plus TislelizumabActive comparator

Patients in this group will receive Tislelizumab consolidation (200 mg/q3w) after the neoadjuvant chemotherapy plus Tislelizumab and concurrent chemoradiotherapy.

Drugs: Neoadjuvant chemo-immunotherapy, Bevacizumab, Tislelizumab

Radiation: Radiotherapy

Sites

1 site in 1 country

  • Sun Yat-sen UniversityGuangzhou, China